Adjusting adalimumab dose for children with eye inflammation
Part of Eyes & vision clinical trials.
This trial tests whether adjusting the dose of adalimumab (a medicine used to treat inflammation) can keep eye inflammation under control in children with juvenile idiopathic arthritis or chronic anterior uveitis. If you or your child have had stable eye inflammation for at least 2 years while on adalimumab, this study may help find the best long-term dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have juvenile idiopathic arthritis or chronic anterior uveitis that started before age 16.
- Must be at least 2 years old and weigh 15 kilograms (33 pounds) or more.
- Eye inflammation must have been controlled (no active swelling or damage) for at least 2 years.
- Must have been taking adalimumab (or a biosimilar) steadily for at least 2 years, with the same dose for the last 6 months.
- Must be able to get adalimumab from a pharmacy (commercial supply).
- If on other arthritis medications, the dose must be stable for at least 3 months and within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special imaging test (not the standard flashlight exam) to screen for eye inflammation (uveitis) in children with juvenile idiopathic arthritis. It aims to see if this new method is better at catching uveitis early.
This study tests whether a lower dose of adalimumab (a biologic medication) can keep controlling chronic non-infectious uveitis (eye inflammation that is not caused by an infection) after it has been well-controlled for a long time. If you have stable eye inflammation and have been on the standard adalimumab dose (40 mg every 2 weeks) for at least 24 weeks, this trial may be suitable for you.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
Hear when a new Uveitis, Anterior trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.